Sep 06, 2021

The Taizhou Antibody Industrial Base of Mabwell Successfully Passed the EU QP Audit

➞

Aug 26, 2021

Mabwell and FEGO Reached Cooperation Agreement on the Commercialization of a Proposed Biosimilar of Adalimumab

➞

Aug 20, 2021

Mabwell Receives IND Clearance from FDA for Initiating Clinical Trials for its Anti-CD47/PD-L1 Bispecific Antibody

➞

Aug 10, 2021

NMPA Accepted IND Application of China's First Anti-Nectin-4 ADC Drug

➞

Aug 08, 2021

Give a Better Play to Hardcore Strengths of Harnessing Science and Technology to Combat COVID-19 Epidemic - Zhang Quan, Director of Science and Technology Commission of Shanghai Municipality, made an inspection to Mabwell

➞

Aug 02, 2021

Mabwell Was Included in the "List of New and Innovative Chinese Pharmaceutical Forces 2021"

➞

Jul 21, 2021

Mabwell's Anti-CD47/PD-L1 Bispecific Antibody 6MW3211 Receives IND Approval in China

➞

Jul 20, 2021

Activity Review | Harmony and Advancement, Deep Cultivation and Empowerment - Mabwell The 4th Science & Technology Conference

➞

Jul 09, 2021

Mabwell and Fudan University Shanghai Cancer Center Announce Strategic Cooperation

➞

Jul 08, 2021

Mabwell was included into the 2021 Chinese Pharmaceutical Talent Brand

➞